Within our bodies different sites and substances (for example, receptors, ion channels, enzymes or carrier molecules such as proteins) may be linked with certain disease processes. If a new medicine is designed to interact with these sites or substances, they are known as drug targets. New medicines or drug treatments achieve their desired effects by altering the behaviour of function of drug targets.
Our research into specific drug targets has resulted in the development of a first-in-class small molecule drug to restore the function of DNA repair efficiency to prevent DNA damage-induced senescence.
CVP001 is being developed based on this research to improve a range of human cell functions associated with the hallmarks of ageing and age-related diseases including osteoporosis and cancer. Its effects on neurodegenerative conditions including Alzheimer’s disease are also being explored in preclinical research.